| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_924c00c27d29d23f4b501b04d18f1892 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D237-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D237-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502 |
| filingDate |
2008-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0826bdfd5b985b9b5091612a1d0df1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0494b188e2f78594b319ecfb7f8d0c9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36a758155f6a05f513c4a072997d1561 |
| publicationDate |
2013-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2487868-C2 |
| titleOfInvention |
4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluor-benzyl]-2h-phthalazin-1-one |
| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to 4-[3-(4-cyclopropanecarbonyl-piperazin-1-carbonyl)-4-fluor-benzyl]-2H-phthalazin-1-one in the form of a crystalline form L having characteristic peaks on an X-ray powder diffraction pattern presented in the patent claim, to methods for preparing the form L, pharmaceutical formulation containing the form L, and versions of using the form L and formulations containing the form L. n EFFECT: preparing the new crystalline form of the above compound which possesses poly-(ADP)polymerase (PARP) inhibitory activity The form L contains no solvent impurities that enables more accurate dosage of the active compound when treating the patient. n 17 cl, 4 dwg, 6 ex |
| priorityDate |
2007-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |